Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from Bayer

Listen to a deep-dive into optimising treatment sequencing for patients with metastatic colorectal cancer, 3rd line and beyond, from Dr Jenny Seligmann and Dr Shubham Pant.

In the podcast, the experts discuss what clinicians should consider when making treatment decisions. You'll learn about

  • the potential treatment options for patients with advanced mCRC
  • the latest available data
  • which patient considerations are important when making treatment decisions

Clinical Takeaways

  • Molecular profiling has an important role in determining treatment options and sequence

  • Physicians should consider patient characteristics, such as comorbidities, toxicities from prior treatments, and overall performance status

  • Treatment from earlier lines of therapy is critical to treatment decisions in the 3rdline and beyond

  • There are a lot of new developments in the third-line treatment space for mCRC patients

  • Patients should receive as many treatment options as possible, and this should be considered during sequencing decisions

Dr Jenny Seligmann gained her MBChB and BMedSci at the University of Aberdeen in 2005 then gained her PhD in 2015 from the University of Leeds on Biomarkers of Prognosis and Prediction of Response in Colorectal Cancer. She was appointed a Cancer Research UK Clinical Trials Fellow in 2015, then a University Academic Fellow and Consultant in Medical Oncology in Leeds in 2017. Her research interests are in clinical trials and biomarkers of prediction of response in colorectal cancer. She is involved in several ongoing clinical trials, including the FOCUS-4 trial and has an ongoing lab-based programme of research. She has been involved in several national and international committees, including the UK Colorectal Clinical Studies Group and is currently the EORTC GI Group Young Investigator. She has received several awards including an ASCO Merit Award in 2013.

Prof. Jenny Seligmann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Merck Serono, Pierre Fabre and Roche Diagnostics. 

Prof. Shubham Pant is a Hematologist-Oncologist and an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston. He previously served as the Director of Clinical Trials for the Section of Hematology-Oncology and Associate Director of the Tobacco Settlement Endowment Trust (TSET) Phase 1 program, for the Stephenson Cancer Center in Oklahoma City. Furthermore Prof. Pant was the Oncology Lead of the Clinical Research Disease Site Group for Gastrointestinal Cancers and Clinical Research Disease Site Group Chair for Hepatocellular Cancers at the same institute. Prof. Pant completed his fellowship from the Ohio State University, where he was elected Chief Fellow. He previously served as an elected member at large to the Board of Directors for Cancer and Leukemia Group B (CALGB), was the Site Principal Investigator for CALGB and was a Member of the Board of Trustees for ACTION. Prof. Pant served on the Board of Oklahoma Society of Clinical Oncology. He is a participant in the ASCO Leadership Development Program, Class of 2015-16. His awards include the Golden Pillar Award for Outstanding Patient Service in 2012 and 2014, America’s Top Doctors by Castle Connolly and Oklahoma 40 Under 40 in the Oklahoma Magazine. In 2015, he anchored a health show on CNN-IBN India titled: ‘Let’s Talk Health’.

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Zymeworks, Ipsen, Novartis, Janssen, Mirati Therapeutics, Pfizer, Lilly, Xencor, BMS, Astellas Pharma, Purple Biotech, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Arcus Biosciences, Elicio Therapeutics, BioNTech

Experts
Prof. Sebastian Stintzing, Dr Juan Manuel O'Connor
  • download Downloadable
    Resouces
  • clock 9 MIN
  • user 3434 HCPs
  • calendar Jan 2023
This educational programme is supported by an Independent Medical Education Grant from Bayer
Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and BeiGene Europe.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resouces
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
tweetorial Tweetorial
Oncology 
Tweetorial video: Navigating ER+ metastatic breast cancer

Explore a patient case from testing, diagnosis and treatment

Experts
Dr Paolo Tarantino
Endorsed by
GRASP
  • clock 9 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Experts
Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
Oncology 
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
Oncology 
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Experts
Prof. Laurence Albiges
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Oncology 
Lung cancer highlights from ESMO 2023

An expert panel discussion hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.